This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
Alzheimer Disease
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
[18F]PI-2620 Phase 3 Histopathological Study
-
Barrow Neurological Institute, Phoenix, Arizona, United States, 85013
Banner Sun Health Research Institute, Sun City, Arizona, United States, 85352
UC Los Angeles, Los Angeles, California, United States, 90095 - 7370
Sutter Health, San Francisco, California, United States, 94114
Galiz Research, Hialeah, Florida, United States, 33016
UF College of Medicine - Jacksonville, Jacksonville, Florida, United States, 32209
K2 Medical Research, Lady Lake, Florida, United States, 32159
ClinCloud Research, Maitland, Florida, United States, 32751
K2 Medical Research, Maitland, Florida, United States, 32751
Miami Jewish Health Systems, Miami, Florida, United States, 33137
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
50 Years to
ALL
No
Life Molecular Imaging Ltd,
Alireza Atri, MD, PhD, PRINCIPAL_INVESTIGATOR, Banner Health
Andrew Stephens, MD, PhD, STUDY_DIRECTOR, Life Molecular Imaging
2026-03